缓释氟尿嘧啶植入剂在大肠癌患者的药动学研究  

Pharmacokinetics of sustained release fluorouracil for implant in patients with intestinal carcinoma

作　　者：刘华顶[1] 王世亮[2] 武四化 储成顶[2] 俞敏[2] 吴静[2] 

机构地区：[1]安徽省阜阳肿瘤医院,阜阳236018 [2]合肥工业大学控释药物研究室,合肥230009

出　　处：《中国新药杂志》2005年第10期1199-1201,共3页Chinese Journal of New Drugs

基　　金：国家科技部基础研究项目(国科基字2001-51#);安徽省教育厅2003教学立项项目

摘　　要：目的:研究缓释氟尿嘧啶植入剂术中植入治疗大肠癌的体内药动学特征。方法:24例大肠癌患者根治术后,关腹前分多点植入缓释氟尿嘧啶,定时采集血样,以高效液相色谱法检测血中氟尿嘧啶浓度。结果:药动学为一室模型,Tmax=72 h,Cmax=(0.56±0.23)μg.mL-1,维持0.1μg.mL-1以上浓度达20 d,AUC达140μg.h.mL-1。24例患者均顺利完成实验,未见不良反应。结论:术中植入缓释氟尿嘧啶后,有典型的药动学特征,对指导临床用药具有积极意义。Objective：To study pharmacokinetic profiles of sustained release 5-fluorouracil for implant in patients with intestinal carcinoma. Methods： 24 patients undergoing radical operations of intestinal carcinoma were abdominally implanted with the sustained release fluorouracil at the closure of abdominal surgery. The plasma fluorouracil concentrations were monitored by HPLC. Results： The pharmacokinetics profile met characteristics of a one-compartment model with Tmax of 72 hours, Cmax= of （0.56 ＋- 0.23）μg· mL^- 1 , AUC of 140 μg· h· mL^- 1 and the sustained plateau of concentrations 0.1 μg· mL^- 1 or above for 20 days. Patients tolerated the fluorouracil for implant well and no adverse events were reported. Conclusion：The sustained release fluorouracil with a prime pharmacokinetics profile showed impressive prognosis.

关 键 词：药动学 大肠癌 缓释氟尿嘧啶植入剂 高效液相色谱法 

分 类 号：R969.1[医药卫生—药理学] R979.12[医药卫生—药学]